18 research outputs found
Résultats à long terme de l'infliximab chez les patients présentant des lésions ano-périnéales non fistulisantes de maladie de Crohn
Introduction : Dans la maladie de Crohn, les ulcĂ©rations anales et les stĂ©noses peuvent ĂȘtre invalidantes. Objectif : Evaluer les rĂ©sullats Ă long terme chez les patients porteurs d'une maladie de Crohn pĂ©rinĂ©ale non fistulisante traitĂ©s par intliximab. MĂ©thode : Les dossiers mĂ©dicaux de 99 patients avec une maladie de Crohn pĂ©rinĂ©ale non fistulisante lors de la 1Ăšre injection ont Ă©tĂ© Ă©tudiĂ©s. Nous avons Ă©valuĂ© les rĂ©ponses complĂštes (cicatrisation des ulcĂšrations et rĂ©gression des stĂ©noses) aprĂšs induction du traitement par infliximab et au terme de la pĂ©riode de suivi. RĂ©sultats : Quatre-vingt-quatorze patients (94,9%) avaient une ulcĂ©ration, 22 (22,2%) avaient une stĂ©nose et 31 (31,3%) avaient une fistule pĂ©rinĂ©ale drainĂ©e lors de la 1Ăšre perfusion d'infliximab. AprĂšs induction du traitement par infliximab, 40/94 (42,5%) des patients avec ulcĂ©ration, 4122 (18,2%) des patients avec stĂ©nose et 10/31 (32 ,2%) des patients avec fistule avaient une rĂ©ponse complĂ©te. Huit patients Ă©taient perdus de vue. AprĂšs un suivi mĂ©dian de 175 semaines (13 Ă 459) , les taux de rĂ©ponses complĂštes pour les ulcĂšres, les stĂ©noses et les fistules Ă©taient respectivement de 72,3% (68/94), 54,5% (12/22) et 54,8% (20/3 1). La rĂ©ponse Ă long terme pour les ulcĂšres profonds Ă©tait associĂ©e Ă la prise concomitante d'un immunosuppresseur (P=0,017) et Ă l'Ăąge des patients (P=0,049). Parmi les 12 patients prĂ©sentant une rĂ©gression complĂšte de leur stĂ©nose, 6 bĂ©nĂ©ficiaient en mĂȘme temps de dilatations anales. La rĂ©ponse complĂšte Ă©tait associĂ©e au soulagement des douleurs pĂ©rinĂ©ales et Ă la disparition des Ă©coulements. Trois patients avec des ulcĂšres ont dĂ©veloppĂ© un abcĂšs. Conclusion : Le traitement par infliximab est probablement efficace dans l'induction et le maintien de la rĂ©ponse clinique pour les ulcĂ©rations pĂ©rinĂ©ales.NANCY1-SCD Medecine (545472101) / SudocNANCY1-Bib. numĂ©rique (543959902) / SudocSudocFranceF
Adjuvant therapy of localized gastrointestinal stromal tumors
Le risque de rĂ©cidive dâune tumeur stromale gastro-intestinale
(GIST) localisĂ©e aprĂšs rĂ©section R0 doit actuellement ĂȘtre
évalué par la classification AFIP (Armed Forces Institute of
Pathology) qui tient compte de la localisation, la taille, et lâindex
mitotique de la tumeur. Une étude randomisée réalisée chez
713 patients, comparant imatinib postopératoire et placebo
pendant 1 an, a montré une diminution significative du risque de
récidive chez les patients traités par imatinib. Cette amélioration
de la survie sans rechute Ă©tait observĂ©e dans les sous-groupes Ă
risque modĂ©rĂ© ou Ă©levĂ© de la classification de lâAFIP, mais pas
dans les sous-groupes à faible et trÚs faible risque de récidive.
Lâimatinib a obtenu rĂ©cemment une AMM en situation adjuvante,
mais lâimpact du traitement Ă long terme, les indications thĂ©rapeutiques
précises et la durée optimale du traitement ne sont pas
clairement Ă©tablis. Les Ă©tudes en cours devraient permettre de
mieux prĂ©ciser la place de lâimatinib en situation adjuvante.The risk of recurrence after resection of a localized GastroIntestinal
Stromal Tumor (GIST) should nowadays be estimated according
to the AFIP (Armed Forces Institute of Pathology) classification,
which takes into account the location, the size and the mitotic
index of the tumor. A clinical trial in which 713 patients were randomly
assigned to receive either imatinib or a placebo for one
year after R0 resection of a localized GIST, showed a significant
decrease of recurrence in patients treated by imatinib. The benefit
was observed in patients with high or moderate risk of recurrence,
but not in case of low or very low risk. Imatinib was recently
approved for adjuvant therapy in GIST, but the long term benefit
of this treatment, its optimal duration and indications are not precisely
defined. Ongoing studies should allow to precise the place
of imatinib as adjuvant therapy in GIST
Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma
This paper reports the first case of a patient with hepatocellular carcinoma with lymph node metastasis treated by sorafenib combined with gemcitabine plus oxaliplatin, with a partial response and normalization of α fetoprotein, which allowed curative surgery. The potential synergy between these three drugs needs to be confirmed, and is currently being investigated in a randomized phase II trial
Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma
International audienceIn metastatic pancreatic adenocarcinoma, a high neutrophil-to-lymphocyte ratio (NLR) at diagnosis is a marker of poor prognosis. The prognostic role of baseline NLR and NLR change during first-line chemotherapy were determined. We conducted a retrospective study by using data from a single-center prospective cohort and a randomized open-label, multicenter, randomized trial. Two hundred and twelve patients were analyzed. Baseline NLR>5 was an independent marker of poor prognosis for overall survival (HR=2.01, 95% CI 1.33-3.05; P=0.001) and progression-free survival (PFS; HR=1.80, 95% CI 1.23-2.65; P=0.0026). According to NLR dynamics (n=172), patients with NLRâ€5 on days 1 and 15 had a significantly better prognosis than those with NLRâ€5 on day 1 and NLR>5 on day 15 (HR=2.23, 95% CI 1.18-4.21; P=0.013), NLR >5 on day 1 and NLR â€5 on day 15 (HR=3.25, 95% CI 1.86-5.68; P5 on days 1 and 15 (HR=3.37, 95% CI 1.93-5.90; P6 months; group effect: P5 had circulating tumor DNA. This study confirmed the independent prognostic value of baseline NLR >5 in metastatic pancreatic cancer. The change in NLR early during chemotherapy was also a prognostic indicator in patients with NLR â€5
Monitoring levels of circulating cellâfree DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
International audienceCirculating cell-free DNA (cfDNA) contains circulating tumor DNA (ctDNA), which can be obtained from serial liquid biopsies to enable tumor genome analysis throughout the course of treatment. We investigated cfDNA and mutant ctDNA as potential biomarkers to predict the best outcomes of regorafenib-treated metastatic colorectal cancer (mCRC) patients. We analyzed longitudinally collected plasma cfDNA of 43 mCRC patients prospectively enrolled in the phase II TEXCAN trial by IntPlex qPCR. Qualitative (KRAS, NRAS, BRAFV600E mutations) and quantitative (total cfDNA concentration, mutant ctDNA concentration, mutant ctDNA fraction) parameters were correlated with overall survival (OS) and progression-free survival (PFS). When examined as classes or continuous variables, the concentrations of total cfDNA, mutant ctDNA, and partly, mutant ctDNA fraction prior to regorafenib treatment correlated with OS. Patients with baseline-cfDNA >26 ng/mL had shorter OS than those with cfDNA value below this threshold (4.0 vs 6.9 months; logrank P=0.0366). Patients with baseline mutant ctDNA >2 ng/mL had shorter OS than those with mutant ctDNA below this threshold (logrank P=0.0154). We show that pre-treatment cfDNA and mutant ctDNA levels may identify mCRC patients that may benefit from regorafenib treatment
Immunothérapie et patients traités pour cancer avec instabilité des microsatellites
International audienceMicrosatellite instability (MSI) is a tumor phenotype linked to somatic or germline (Lynch syndrome) inactivating alterations of DNA mismatch repair genes. A broad spectrum of neoplasms exhibits MSI phenotype, mainly colorectal cancer, endometrial cancer, and gastric cancer. MSI tumors are characterized by dense immune infiltration and high load of tumor neo-antigens. Growing evidence is accumulating on the efficacy of immune checkpoint inhibition for patients treated for MSI solid tumors. We present a comprehensive overview of MSI phenotype, its biological landscape and current diagnostic methods. Then we focus on MSI as a predictive biomarker of response to immune checkpoint inhibition in the context of colorectal cancer and non-colorectal tumors.LâinstabilitĂ© des microsatellites (MSI) est un phĂ©notype tumoral liĂ© Ă lâinactivation somatique ou constitutionnelle (syndrome de Lynch) des gĂšnes de rĂ©paration des mĂ©sappairements de lâADN. Un large spectre de localisations tumorales prĂ©sente un phĂ©notype MSI, principalement le cancer colorectal, le cancer de lâendomĂštre et le cancer de lâestomac. Les tumeurs MSI sont caractĂ©risĂ©es par un infiltrat inflammatoire important et une charge importante en nĂ©o-antigĂšnes tumoraux. Les stratĂ©gies thĂ©rapeutiques ciblant les points de contrĂŽle immunitaires semblent efficaces chez ces patients. Cette revue de la littĂ©rature prĂ©sente les consĂ©quences physiopathologiques et les mĂ©thodes diagnostiques du phĂ©notype tumoral MSI, pour sâintĂ©resser ensuite Ă lâĂ©pidĂ©miologie des tumeurs MSI et aux donnĂ©es actualisĂ©es concernant lâimmunothĂ©rapie chez les patients prĂ©sentant des tumeurs MSI, cancer colorectal et autres tumeurs solides associĂ©es au phĂ©notype MSI
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study
FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
International audienc
Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial
<div><p>Background</p><p>A randomized multicenter phase II trial was conducted to assess the sequential treatment strategy using FOLFIRI.3 and gemcitabine alternately (Arm 2) compared to gemcitabine alone (Arm 1) in patients with metastatic non pre-treated pancreatic adenocarcinoma. The primary endpoint was the progression-free survival (PFS) rate at 6 months. It concludes that the sequential treatment strategy appears to be feasible and effective with a PFS rate of 43.5% in Arm 2 at 6 months (26.1% in Arm 1). This paper reports the results of the longitudinal analysis of the health-related quality of life (HRQoL) as a secondary endpoint of this study.</p><p>Methods</p><p>HRQoL was evaluated using the EORTC QLQ-C30 at baseline and every two months until the end of the study or death. HRQoL deterioration-free survival (QFS) was defined as the time from randomization to a first significant deterioration as compared to the baseline score with no further significant improvement, or death. A propensity score was estimated comparing characteristics of partial and complete responders. Analyses were repeated with inverse probability weighting method using the propensity score. Multivariate Cox regression analyses were performed to identify independent factors influencing QFS.</p><p>Results</p><p>98 patients were included between 2007 and 2011. Adjusting on the propensity score, patients of Arm 2 presented a longer QFS of Global Health Status (Hazard Ratio: 0.52 [0.31-0.85]), emotional functioning (0.35 [0.21â0.59]) and pain (0.50 [0.31 â 0.81]) than those of Arm 1.</p><p>Conclusion</p><p>Patients of Arm 2 presented a better HRQoL with a longer QFS than those of Arm 1. Moreover, the propensity score method allows to take into account the missing data depending on patientsâ characteristics.</p><p>Trial registration information</p><p>Eudract N° <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005703-34/FR" target="_blank">2006-005703-34</a>. (Name of the Trial: FIRGEM).</p></div